Two additional Spanish centers announce adoption of the Xoft System, totaling seven installations across four major regions in Spain
Internationally-recognized institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s state-of-the-art electronic brachytherapy technology
NASHUA, N.H., April 15, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Catalan Institute of Oncology (ICO), a leading, multi-center cancer organization in Spain, has selected iCAD as the provider of electronic brachytherapy technology for the treatment of early-stage breast cancer and gynecological cancers. ICO will introduce iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at three hospitals located in L'Hospitalet de Llobregat, Badalona, and Girona, Spain.
In addition, New Cáceres Hospital in Cáceres and Obispo Polanco Hospital in Teruel have also adopted the Xoft System for the treatment of early-stage breast cancer, gynecological cancers, and non-melanoma skin cancer. The deals were completed in partnership with Aplicaciones Tecnológicas S.A., the distributor of the Xoft System in Spain.
With the addition of these facilities, Xoft treatments will now be available at seven Spanish hospitals, including Hospital Universitario Miguel Servet in Zaragoza and Hospital Clinico Universitario in Salamanca, providing cancer treatment services in four of the most densely populated regions of Spain: Catalonia, Aragon, Castile and León, and Extremadura.
“We are pleased to partner with these world-class institutions to provide unprecedented access to our revolutionary technology in Spain,” said Stacey Stevens, President of iCAD. “As global adoption of the Xoft System continues to expand, we look forward to continuing to provide patients and clinicians worldwide with our unique and versatile platform solution offering proven benefits in treating a range of cancers.”
ICO will offer Xoft treatments at ICO L’Hospitalet – Bellvitge University Hospital, ICO Badalona – Germans Trias i Pujol University Hospital and ICO Girona – Doctor Josep Trueta University Hospital. With an established network of partnerships throughout the region, ICO serves as the referral center for 60 percent of the adult population in Catalonia. Following the Comprehensive Cancer Centre model defined by the European Organization of Cancer Institutes, ICO takes an integrated, full-service approach to cancer care including prevention, care, specialized training, and research. To date, it is the only organization of its kind in Spain.
"In our thorough review of cutting-edge radiation therapy technology available today, the Xoft System’s distinguished versatility across a variety of clinical applications, mobility, and unique benefits for both patients and clinicians made it the optimal solution for our organization,” said Carles Muñoz, Technology and Physics Manager at ICO. “The Xoft System seamlessly aligns with our mission to reduce the impact of cancer through advanced treatments that deliver high-quality, effective outcomes, and we are proud to offer this new option to patients in the region.”
The Xoft System is a proprietary electronic brachytherapy platform designed to deliver isotope-free (non-radioactive) radiation therapy. It is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It uses a miniaturized x-ray source to deliver targeted radiation directly to the cancerous site, sparing healthy tissues and surrounding organs. The Xoft System is highly mobile and requires minimal shielding, allowing it to be used in a variety of clinical settings and eliminating the need for room redesign or construction investment. For more information, please visit www.xoftinc.com.
About iCAD, Inc.
Headquartered in Nashua, N.H., iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
About Institute of Oncology in Catalonia (ICO)
The Catalan Institute of Oncology (ICO) is a public center working exclusively in the field of cancer. Its approach to the disease is comprehensive, combining, all in one organization, prevention, care, specialized training and research. The ICO is a public company created in 1995 by the Ministry of Health of the Government of Catalonia. It went into service a year later, operating from the Duran i Reynals Hospital in L'Hospitalet de Llobregat. Seven years later, in 2002, ICO Girona opened its doors, located in Doctor Josep Trueta University Hospital, followed by ICO Badalona a year later, at the Germans Trias i Pujol University Hospital. In 2014, it launched ICO Camp de Tarragona and Terres de l'Ebre, in Joan XXIII University Hospital and Verge de la Cinta Hospital. Currently, ICO is an oncology referral centre 60 percent of the adult population of Catalonia.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568